New targets for cancer therapy.
Coombes
R C
RC
Cancer Research Campaign Laboratories, Charing Cross and Westminster Medical School, London, U.K.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D015195:Drug Design; D004341:Drug Evaluation / Q000379:methods; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D004967:Estrogens / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D015316:Genetic Therapy; D006131:Growth Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D016372:RNA, Antisense / Q000494:pharmacology / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000502:physiology; D012176:Retinoids / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D014807:Vitamin D / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D004967:Estrogens; D006131:Growth Inhibitors; D006133:Growth Substances; D011518:Proto-Oncogene Proteins; D016372:RNA, Antisense; D011956:Receptors, Cell Surface; D012176:Retinoids; D014807:Vitamin D